…
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
INmune Bio is a clinical-stage biotechnology company developing therapies that modulate the innate immune system to address cancers and neurodegenerative disorders. Long-term growth may benefit from advancement of clinical-stage programs, validation of its immune‑modulating approach, possible collaborations or licensing, and continuing demand for novel immunotherapies, which could make the company attractive to investors seeking exposure to early-stage, mechanism-driven drug development.
The most important investment risks are clinical and regulatory failure, ongoing capital requirements that could dilute shareholders, and intense competition in oncology and neurology.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -45.93M | -42.08M | -30.01M | -27.30M | -30.34M |
| Net income | -45.93M | -42.08M | -30.01M | -28.65M | -30.34M |
| Selling general administrative | 10.26M | 9.48M | 9.62M | 9.26M | 8.79M |
| Selling and marketing expenses | - | - | 0.16M | - | - |
| Gross profit | 0.05M | 0.01M | 0.15M | 0.37M | 0.18M |
| Reconciled depreciation | 0.08M | 0.00M | - | - | - |
| Ebit | -45.93M | -42.08M | -30.01M | -25.95M | -29.15M |
| Ebitda | -45.85M | -41.53M | -0.27M | -25.95M | -29.15M |
| Depreciation and amortization | 0.08M | 0.55M | 29.74M | -1.35M | -1.19M |
| Non operating income net other | - | - | - | - | -1.19M |
| Operating income | -30.87M | -42.63M | -29.74M | -25.95M | -29.15M |
| Other operating expenses | 30.92M | 42.65M | 29.90M | 26.32M | 29.33M |
| Interest expense | - | - | - | 1.35M | 1.19M |
| Income tax expense | - | - | -29.74M | 1.35M | 1.19M |
| Total revenue | 0.05M | 0.01M | 0.15M | 0.37M | 0.18M |
| Total operating expenses | 30.92M | 42.65M | 29.90M | 26.32M | 29.33M |
| Total other income expense net | -15.06M | 0.55M | -0.27M | -1.35M | -1.19M |
| Net income from continuing ops | -45.93M | -42.08M | -27.43M | -25.95M | -30.34M |
| Net income applicable to common shares | - | - | - | -27.30M | -30.34M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 32.35M | 39.56M | 57.00M | 81.80M | 99.94M |
| Intangible assets | - | 16.51M | 16.51M | 16.51M | 16.51M |
| Other current assets | 0.59M | 0.33M | 1.65M | 4.03M | 7.80M |
| Total liab | 8.83M | 7.46M | 18.86M | 21.69M | 19.72M |
| Total stockholder equity | 23.52M | 32.10M | 38.14M | 60.10M | 80.22M |
| Other current liab | 0.03M | 0.52M | 8.43M | 0.62M | 0.47M |
| Common stock | 0.03M | 0.02M | 0.82M | 0.02M | 0.02M |
| Capital stock | 0.03M | 0.02M | 0.82M | 0.02M | 0.02M |
| Retained earnings | -209.04M | -163.10M | -121.02M | -91.01M | -63.72M |
| Other liab | - | - | - | 0.55M | 0.20M |
| Other assets | - | - | 0.00M | 0.10M | 0.10M |
| Cash | 24.75M | 20.92M | 35.85M | 52.15M | 74.81M |
| Total current liabilities | 8.42M | 7.22M | 18.46M | 10.92M | 4.36M |
| Current deferred revenue | - | - | 0.49M | - | - |
| Net debt | -23.72M | -20.54M | -25.41M | -36.84M | -59.58M |
| Short term debt | 0.62M | 0.14M | 10.04M | 5.09M | 0.07M |
| Short long term debt | - | - | 9.92M | 5.00M | - |
| Short long term debt total | 1.03M | 0.38M | 10.44M | 15.31M | 15.23M |
| Other stockholder equity | 233.27M | 195.75M | 158.34M | 151.80M | 143.92M |
| Property plant equipment | - | - | - | 0.51M | 0.73M |
| Total current assets | 29.89M | 22.66M | 39.94M | 64.67M | 82.61M |
| Net tangible assets | - | - | - | 43.59M | 63.71M |
| Net receivables | 4.54M | 1.41M | 2.44M | 8.46M | 5.50M |
| Long term debt | - | - | - | 9.70M | 14.46M |
| Inventory | - | - | - | 0.03M | -5.50M |
| Accounts payable | 7.77M | 6.56M | 7.94M | 5.21M | 3.81M |
| Accumulated other comprehensive income | -0.74M | -0.57M | -0.80M | -0.70M | 0.00M |
| Common stock total equity | - | - | - | 0.02M | 0.02M |
| Retained earnings total equity | - | - | - | -91.01M | -63.72M |
| Non currrent assets other | 1.55M | 0.08M | 0.13M | 0.10M | 0.10M |
| Non current assets total | 2.46M | 16.90M | 17.06M | 17.12M | 17.34M |
| Capital lease obligations | 1.03M | 0.38M | 0.52M | 0.61M | 0.78M |
| Long term debt total | - | - | - | 9.70M | 14.46M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | - | 0.00M | -15.00M |
| Change to liabilities | - | - | - | 1.75M | 2.46M |
| Total cashflows from investing activities | -1.04M | - | - | - | -15.00M |
| Net borrowings | 0.00M | -10.00M | -5.00M | - | 14.95M |
| Total cash from financing activities | 27.61M | 18.21M | -4.22M | 0.73M | 96.36M |
| Change to operating activities | - | - | - | -4.27M | -5.35M |
| Net income | -45.93M | -42.08M | -30.01M | -27.30M | -30.34M |
| Change in cash | 3.83M | -14.93M | -16.30M | -22.66M | 52.84M |
| Begin period cash flow | 20.92M | 35.85M | 52.15M | 74.81M | 21.97M |
| End period cash flow | 24.75M | 20.92M | 35.85M | 52.15M | 74.81M |
| Total cash from operating activities | -22.58M | -33.36M | -11.98M | -22.69M | -28.50M |
| Issuance of capital stock | 27.54M | 27.79M | 0.78M | 0.70M | 80.25M |
| Depreciation | 0.08M | 0.00M | 0.22M | 0.24M | 0.13M |
| Other cashflows from investing activities | -1.04M | - | - | - | -15.00M |
| Change to account receivables | -3.13M | 1.03M | 6.02M | - | - |
| Sale purchase of stock | - | - | - | 0.03M | 81.41M |
| Other cashflows from financing activities | 27.61M | 0.42M | 0.78M | 0.03M | 16.10M |
| Change to netincome | - | - | - | 7.15M | 4.80M |
| Capital expenditures | 1.04M | 0.00M | 0.00M | 0.00M | 15.00M |
| Change receivables | - | - | - | 0.23M | - |
| Cash flows other operating | - | - | - | -4.76M | -5.55M |
| Exchange rate changes | - | - | - | - | -0.01M |
| Cash and cash equivalents changes | - | - | - | -21.96M | 52.84M |
| Change in working capital | -2.53M | 1.04M | 10.44M | -2.86M | -3.09M |
| Stock based compensation | 9.91M | 7.61M | 7.37M | 7.15M | 4.80M |
| Other non cash items | 15.89M | 0.08M | 0.22M | 0.33M | 0.13M |
| Free cash flow | -23.62M | -33.36M | -11.98M | -22.69M | -43.50M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INMB INmune Bio Inc |
-0.01 0.96% |
1.03 | - | - | 760.34 | 3.19 | 286.00 | -5.31 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Name | Title | Year Born |
|---|---|---|
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, Pres, CEO, Chief Medical Officer & Chairman | 1956 |
| Mr. David J. Moss M.B.A. | CFO, Treasurer & Sec. | 1970 |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Chief Scientific Officer & Chief Manufacturing Officer | 1963 |
| Mr. Joshua S. Schoonover Esq. | Assoc. Gen. Counsel | NA |
| Dr. Christopher J. Barnum | Head of Neuroscience | NA |
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, President, CEO, Chief Medical Officer & Chairman | 1956 |
| Mr. David J. Moss M.B.A. | CFO, Treasurer & Secretary | 1970 |
| Mr. Joshua S. Schoonover Esq. | General Counsel | NA |
| Mr. David J. Moss M.B.A. | President, CEO, Treasurer, Secretary & Director | 1970 |
| Mr. Cory Randall Ellspermann | Interim Chief Financial Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.